tirzepatide + cyanocobalamin Eli Lilly Releases Open Letter Warning of Potential Safety Risks for Compounded Plus Vitamin B12 Compounded Tirzepatide

We aim to keep product information accurate and up to date, but manufacturer information may change

Providers typically prescribe these medications to people with a body mass index of 30 or higher or those with a BMI of 27 or higher who also have weight-related health conditions such as Type 2 diabetes, high blood pressure, or high cholesterol

Tirzepatide is one of the newest weight loss prescriptions that can help people shed weight and regain their sense of self

5 NonHabitForming Support vs

1,4 Adverse events 5% in SUSTAIN 5 8,10 AEs occurring in 5% of participants treated with Ozempic injection in SUSTAIN 5 Incidence of severe hypoglycemia was 1.5% across all placebo-controlled trials 1 Incidence of severe hypoglycemia or blood glucose-confirmed hypoglycemia (% of patients) was 8,10 : 8.3% with Ozempic 0.5 mg + basal insulin MET 10.7% with Ozempic 1 mg + basal insulin MET 5.3% with placebo + basal insulin MET Patients receiving Ozempic injection in combination with an insulin secretagogue (eg, sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia 1 Adverse events 5% in SUSTAIN FORTE 4 AEs occurring in 5% of patients receiving Ozempic injection 1 mg and 2 mg in SUSTAIN FORTE In placebo-controlled trials, the most common adverse reactions reported in 5% of patients treated with Ozempic injection are nausea, vomiting, diarrhea, abdominal pain, and constipation 1 No new safety signals were identified